Shares of HLS Therapeutics Inc. (OTCMKTS:HLTRF – Get Free Report) passed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $3.10 and traded as low as $3.03. HLS Therapeutics shares last traded at $3.05, with a volume of 2,220 shares.
Analyst Upgrades and Downgrades
Separately, Raymond James Financial upgraded HLS Therapeutics from an “outperform” rating to a “strong-buy” rating in a report on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating. According to MarketBeat, the stock presently has a consensus rating of “Strong Buy”.
Check Out Our Latest Research Report on HLS Therapeutics
HLS Therapeutics Trading Down 3.2%
The stock’s 50-day simple moving average is $2.82 and its 200 day simple moving average is $3.10.
About HLS Therapeutics
HLS Therapeutics Inc is a specialty pharmaceutical company focused on acquiring, licensing, developing and commercializing prescription medicines. Rather than primarily discovering new drugs, the company generally builds value by obtaining rights to established or differentiated pharmaceutical products and supporting their regulatory approval, market access and commercial distribution.
The company’s activities have centered on specialty-care and hospital-related therapies, including products for central nervous system and cardiovascular conditions.
Read More
- Five stocks we like better than HLS Therapeutics
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
